NCCN Breast Cancer Guidelines

New NCCN Breast Cancer Guidelines recognize Oncotype DX Breast Recurrence Score® as the “preferred” and only multigene test to predict chemotherapy benefit in node-positive early-stage breast cancer

Exact Sciences at 2021 ASCO Annual Meeting

Landmark RxPONDER Trial Results

Presented at the 2020 SABCS

New data clarifies the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Recurrence Score® results of 0 to 25
Making cancer care smarter.®
X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.